• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于肽微阵列的 SARS-CoV-2 抗体反应分析鉴定出具有潜在诊断测试开发价值的独特表位。

Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.

机构信息

JPT Peptide Technologies GmbH, Berlin, Germany.

Institute for Molecular Diagnostics and Bioanalysis-IMDB gGmbH, Hennigsdorf, Germany.

出版信息

Eur J Immunol. 2021 Jul;51(7):1839-1849. doi: 10.1002/eji.202049101. Epub 2021 May 7.

DOI:10.1002/eji.202049101
PMID:33772767
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8250065/
Abstract

Humoral immunity to the Severe Adult Respiratory Syndrome (SARS) Coronavirus (CoV)-2 is not fully understood yet but is a crucial factor of immune protection. The possibility of antibody cross-reactivity between SARS-CoV-2 and other human coronaviruses (HCoVs) would have important implications for immune protection but also for the development of specific diagnostic ELISA tests. Using peptide microarrays, n = 24 patient samples and n = 12 control samples were screened for antibodies against the entire SARS-CoV-2 proteome as well as the Spike (S), Nucleocapsid (N), VME1 (V), R1ab, and Protein 3a (AP3A) of the HCoV strains SARS, MERS, OC43, and 229E. While widespread cross-reactivity was revealed across several immunodominant regions of S and N, IgG binding to several SARS-CoV-2-derived peptides provided statistically significant discrimination between COVID-19 patients and controls. Selected target peptides may serve as capture antigens for future, highly COVID-19-specific diagnostic antibody tests.

摘要

体液免疫对严重急性呼吸综合征（SARS）冠状病毒（CoV）-2 的了解还不完全，但它是免疫保护的一个关键因素。SARS-CoV-2 与其他人类冠状病毒（HCoV）之间抗体交叉反应的可能性对免疫保护具有重要意义，但也对特异性诊断 ELISA 检测的发展具有重要意义。使用肽微阵列，对 n = 24 例患者样本和 n = 12 例对照样本进行了针对 SARS-CoV-2 整个蛋白质组以及 SARS、MERS、OC43 和 229E 型 HCoV 的 Spike（S）、核衣壳（N）、VME1（V）、R1ab 和蛋白 3a（AP3A）的抗体筛选。虽然在 S 和 N 的几个免疫优势区域发现了广泛的交叉反应，但 IgG 与几个 SARS-CoV-2 衍生肽的结合在 COVID-19 患者和对照组之间提供了统计学上显著的区分。选定的靶肽可作为未来高度 COVID-19 特异性诊断抗体检测的捕获抗原。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/37264f5cb675/EJI-51-1839-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/b0541d7e84bd/EJI-51-1839-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/d4b9fc9d8dc9/EJI-51-1839-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/ea3e885c546c/EJI-51-1839-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/6161d4e141c8/EJI-51-1839-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/37264f5cb675/EJI-51-1839-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/b0541d7e84bd/EJI-51-1839-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/d4b9fc9d8dc9/EJI-51-1839-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/ea3e885c546c/EJI-51-1839-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/6161d4e141c8/EJI-51-1839-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8879/8250065/37264f5cb675/EJI-51-1839-g005.jpg

相似文献

1
Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development.基于肽微阵列的 SARS-CoV-2 抗体反应分析鉴定出具有潜在诊断测试开发价值的独特表位。
Eur J Immunol. 2021 Jul;51(7):1839-1849. doi: 10.1002/eji.202049101. Epub 2021 May 7.
2
Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray.利用多冠状病毒蛋白微阵列在 COVID-19 患者中绘制 SARS-CoV-2 抗体表位图谱。
Microbiol Spectr. 2021 Oct 31;9(2):e0141621. doi: 10.1128/Spectrum.01416-21. Epub 2021 Oct 27.
3
Diverse Humoral Immune Responses in Younger and Older Adult COVID-19 Patients.年轻和老年 COVID-19 患者的不同体液免疫反应。
mBio. 2021 Jun 29;12(3):e0122921. doi: 10.1128/mBio.01229-21.
4
Antibody Mediated Immunity to SARS-CoV-2 and Human Coronaviruses: Multiplex Beads Assay and Volumetric Absorptive Microsampling to Generate Immune Repertoire Cartography.SARS-CoV-2 和人类冠状病毒的抗体介导免疫：多重珠粒分析和容量吸附微采样以生成免疫库图谱。
Front Immunol. 2021 Jul 27;12:696370. doi: 10.3389/fimmu.2021.696370. eCollection 2021.
5
Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post-COVID-19 Convalescent Samples.检测血清交叉反应抗体和对 SARS-CoV-2 的记忆反应在大流行前和 COVID-19 后恢复期样本中。
J Infect Dis. 2021 Oct 28;224(8):1305-1315. doi: 10.1093/infdis/jiab333.
6
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.针对人冠状病毒 OC43 刺突蛋白的交叉反应性抗体与 COVID-19 患者的疾病严重程度相关：一项回顾性研究。
Emerg Microbes Infect. 2021 Dec;10(1):664-676. doi: 10.1080/22221751.2021.1905488.
7
Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan.来源于日本健康供体的正常人静脉注射免疫球蛋白对 SARS-CoV-1/2、MERS-CoV 以及人类冠状病毒 229E 和 OC43 的中和及结合活性。
Transfusion. 2021 Feb;61(2):356-360. doi: 10.1111/trf.16161. Epub 2020 Oct 26.
8
Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses.用于定量检测交叉中和抗体反应的所有循环人类冠状病毒的冠状病毒假型。
Viruses. 2021 Aug 10;13(8):1579. doi: 10.3390/v13081579.
9
Anti-RBD IgG antibodies from endemic coronaviruses do not protect against the acquisition of SARS-CoV-2 infection among exposed uninfected individuals.地方性冠状病毒的抗 RBD IgG 抗体不能预防暴露于未感染者中 SARS-CoV-2 感染的发生。
Front Immunol. 2024 May 23;15:1396603. doi: 10.3389/fimmu.2024.1396603. eCollection 2024.
10
Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.严重急性呼吸综合征相关冠状病毒与人类冠状病毒229E和OC43之间的抗原交叉反应性。
J Infect Dis. 2005 Jun 15;191(12):2033-7. doi: 10.1086/430355. Epub 2005 May 6.

引用本文的文献

1
Peptide immunoarrays for rationale development of vaccines with enhanced cross-reactivity.用于合理开发具有增强交叉反应性疫苗的肽免疫阵列。
PLoS One. 2025 Sep 4;20(9):e0330741. doi: 10.1371/journal.pone.0330741. eCollection 2025.
2
μSARS2 Chip: A Peptide-Based Microarray to Assess COVID-19 Prognosis Based on Immunological Fingerprints.μSARS2芯片：一种基于肽的微阵列，用于基于免疫指纹评估新冠肺炎预后。
ACS Pharmacol Transl Sci. 2025 Feb 21;8(3):871-884. doi: 10.1021/acsptsci.4c00727. eCollection 2025 Mar 14.
3
Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein.

本文引用的文献

1
Landscape and selection of vaccine epitopes in SARS-CoV-2.SARS-CoV-2 疫苗表位的景观和选择。
Genome Med. 2021 Jun 14;13(1):101. doi: 10.1186/s13073-021-00910-1.
2
COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses.COVID-19 免疫特征表明，尽管抗体反应下降，但抗病毒 T 细胞功能仍保持稳定。
Immunity. 2021 Feb 9;54(2):340-354.e6. doi: 10.1016/j.immuni.2021.01.008.
3
Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses.
增强对刺突蛋白内交叉反应性抗原决定簇的评估。
Int J Mol Sci. 2024 Jul 26;25(15):8180. doi: 10.3390/ijms25158180.
4
A Dynamic and Effective Peptide-Based Strategy for Promptly Addressing Emerging SARS-CoV-2 Variants of Concern.一种动态有效的基于肽的策略，用于迅速应对新出现的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）关注变异株。
Pharmaceuticals (Basel). 2024 Jul 4;17(7):891. doi: 10.3390/ph17070891.
5
Overview of Nucleocapsid-Targeting Vaccines against COVID-19.针对新冠病毒的核衣壳靶向疫苗概述。
Vaccines (Basel). 2023 Dec 3;11(12):1810. doi: 10.3390/vaccines11121810.
6
SARS-CoV-2 Spike protein peptides displayed in the Pyrococcus furiosus RAD system preserve epitopes antigenicity, immunogenicity, and virus-neutralizing activity of antibodies.在嗜热栖热菌RAD系统中展示的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突蛋白肽保留了抗体的表位抗原性、免疫原性和病毒中和活性。
Sci Rep. 2023 Oct 5;13(1):16821. doi: 10.1038/s41598-023-43720-8.
7
SARS-CoV-2 Gut-Targeted Epitopes: Sequence Similarity and Cross-Reactivity Join Together for Molecular Mimicry.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）靶向肠道的表位：序列相似性与交叉反应性共同构成分子模拟
Biomedicines. 2023 Jul 7;11(7):1937. doi: 10.3390/biomedicines11071937.
8
A linear B-cell epitope close to the furin cleavage site within the S1 domain of SARS-CoV-2 Spike protein discriminates the humoral immune response of nucleic acid- and protein-based vaccine cohorts.SARS-CoV-2 刺突蛋白 S1 结构域内靠近弗林蛋白酶切割位点的线性 B 细胞表位可区分基于核酸和蛋白的疫苗接种者的体液免疫反应。
Front Immunol. 2023 May 5;14:1192395. doi: 10.3389/fimmu.2023.1192395. eCollection 2023.
9
Serodominant SARS-CoV-2 Nucleocapsid Peptides Map to Unstructured Protein Regions.优势血清型 SARS-CoV-2 核衣壳肽映射到无规卷曲蛋白区域。
Microbiol Spectr. 2023 Jun 15;11(3):e0032423. doi: 10.1128/spectrum.00324-23. Epub 2023 May 16.
10
Exploring the Immunodominant Epitopes of SARS-CoV-2 Nucleocapsid Protein as Exposure Biomarker.探索新冠病毒核衣壳蛋白的免疫显性表位作为暴露生物标志物
Cureus. 2023 Feb 10;15(2):e34827. doi: 10.7759/cureus.34827. eCollection 2023 Feb.
新冠病毒抗体反应的表位解析分析确定了与地方性人类冠状病毒的交叉反应性。
Cell Rep Med. 2021 Jan 19;2(1):100189. doi: 10.1016/j.xcrm.2020.100189.
4
SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.用于在氨基酸分辨率下绘制新冠病毒抗体相互作用图谱的严重急性呼吸综合征冠状病毒2蛋白质组芯片
ACS Cent Sci. 2020 Dec 23;6(12):2238-2249. doi: 10.1021/acscentsci.0c00742. Epub 2020 Oct 21.
5
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.人类对 SARS-CoV-2 的预先存在和新产生的体液免疫。
Science. 2020 Dec 11;370(6522):1339-1343. doi: 10.1126/science.abe1107. Epub 2020 Nov 6.
6
Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity.对 COVID-19 患者的病毒表位分析揭示了交叉反应性和严重程度的相关性。
Science. 2020 Nov 27;370(6520). doi: 10.1126/science.abd4250. Epub 2020 Sep 29.
7
A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity.冠状病毒抗体介导免疫的系统评价：动力学、保护相关性及与严重程度的关系。
Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4.
8
Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting.评价针对 SARS-CoV-2 的血清学检测：在低流行地区血清学检测的意义。
J Infect Dis. 2020 Sep 14;222(8):1280-1288. doi: 10.1093/infdis/jiaa467.
9
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.未暴露于 SARS-CoV-2 人群中的选择性和交叉反应性 T 细胞表位。
Science. 2020 Oct 2;370(6512):89-94. doi: 10.1126/science.abd3871. Epub 2020 Aug 4.
10
Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France.法国东部轻症住院医护人员对 SARS-CoV-2 感染的血清学反应。
EBioMedicine. 2020 Sep;59:102915. doi: 10.1016/j.ebiom.2020.102915. Epub 2020 Jul 31.